Nucleic Acid Therapeutics Market [Product: Anti-Sense Oligonucleotides (ASO), RNA Interference (RNAi), and RNA Aptamers; and Indication: Autoimmune Disorders, Infectious Diseases, Genetic Disorders, Cancer, and Others] - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
Nucleic Acid Therapeutics Market – Scope of Report TMR’s report on the global nucleic acid therapeutics market studies the past as well as the current growth trends and opportunities to gain valua... もっと見る
日本語のページは自動翻訳を利用し作成しています。
SummaryNucleic Acid Therapeutics Market – Scope of ReportTMR’s report on the global nucleic acid therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global nucleic acid therapeutics market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global nucleic acid therapeutics market from 2024 to 2034. The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the nucleic acid therapeutics market. Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global nucleic acid therapeutics market. The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global nucleic acid therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global nucleic acid therapeutics market. The report delves into the competitive landscape of the global nucleic acid therapeutics market. Key players operating in the global nucleic acid therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global nucleic acid therapeutics market profiled in this report. Key Questions Answered in Global nucleic acid therapeutics Market Report • What is the sales/revenue generated by nucleic acid therapeutics across all regions during the forecast period? • What are the opportunities in the global nucleic acid therapeutics market? • What are the major drivers, restraints, opportunities, and threats in the market? • Which regional market is set to expand at the fastest CAGR during the forecast period? • Which segment is expected to generate the highest revenue globally in 2034? • Which segment is projected to expand at the highest CAGR during the forecast period? • What are the market positions of different companies operating in the global market? Nucleic Acid Therapeutics Market – Research Objectives and Research Approach The comprehensive report on the global nucleic acid therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products. For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period. The report analyzes the global nucleic acid therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global nucleic acid therapeutics market. Table of Contents1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Nucleic Acid Therapeutics Market 4. Market Overview 4.1. Introduction 4.1.1. Segment Definition 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, 2020-2034 4.4.1. Market Revenue Projections (US$ Mn) 5. Key Insights 5.1. Pipeline Analysis 5.2. Regulatory Scenario by Countries 5.3. Technological Advancement 5.4. Reimbursement Scenario 5.5. PESTEL Analysis 5.6. Porter’s Five Force Analysis 5.7. Impact Analysis on Market 5.8. Investment Scenario 5.9. Unmet Needs in Current Treatment Landscape 6. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, By Product 6.1. Introduction & Definition 6.2. Key Findings / Developments 6.3. Market Value Forecast By Product, 2020-2034 6.3.1. Anti-Sense Oligonucleotides (ASO) 6.3.2. RNA Interference (RNAi) 6.3.3. RNA Aptamers 6.4. Market Attractiveness By Product 7. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, By Indication 7.1. Introduction & Definition 7.2. Key Findings / Developments 7.3. Market Value Forecast By Indication, 2020-2034 7.3.1. Autoimmune Disorders 7.3.2. Infectious Diseases 7.3.3. Genetic Disorders 7.3.4. Cancer 7.3.5. Others 7.4. Market Attractiveness By Indication 8. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, By End-user 8.1. Introduction & Definition 8.2. Key Findings / Developments 8.3. Market Value Forecast By End-user, 2020-2034 8.3.1. Hospitals 8.3.2. Physicians’ Offices 8.3.3. Others 8.4. Market Attractiveness By End-user 9. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, By Region 9.1. Key Findings 9.2. Market Value Forecast By Region 9.2.1. North America 9.2.2. Europe 9.2.3. Asia Pacific 9.2.4. Latin America 9.2.5. Middle East & Africa 9.3. Market Attractiveness By Country/Region 10. North America Nucleic Acid Therapeutics Market Analysis and Forecast 10.1. Introduction 10.1.1. Key Findings 10.2. Market Value Forecast By Product, 2020-2034 10.2.1. Anti-Sense Oligonucleotides (ASO) 10.2.2. RNA Interference (RNAi) 10.2.3. RNA Aptamers 10.3. Market Value Forecast By Indication, 2020-2034 10.3.1. Autoimmune Disorders 10.3.2. Infectious Diseases 10.3.3. Genetic Disorders 10.3.4. Cancer 10.3.5. Others 10.4. Market Value Forecast By End-user, 2020-2034 10.4.1. Hospitals 10.4.2. Physicians’ Offices 10.4.3. Others 10.5. Market Value Forecast By Country, 2020-2034 10.5.1. U.S. 10.5.2. Canada 10.6. Market Attractiveness Analysis 10.6.1. By Product 10.6.2. By Indication 10.6.3. By End-user 10.6.4. By Country 11. Europe Nucleic Acid Therapeutics Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast By Product, 2020-2034 11.2.1. Anti-Sense Oligonucleotides (ASO) 11.2.2. RNA Interference (RNAi) 11.2.3. RNA Aptamers 11.3. Market Value Forecast By Indication, 2020-2034 11.3.1. Autoimmune Disorders 11.3.2. Infectious Diseases 11.3.3. Genetic Disorders 11.3.4. Cancer 11.3.5. Others 11.4. Market Value Forecast By End-user, 2020-2034 11.4.1. Hospitals 11.4.2. Physicians’ Offices 11.4.3. Others 11.5. Market Value Forecast By Country/Sub-region, 2020-2034 11.5.1. Germany 11.5.2. U.K. 11.5.3. France 11.5.4. Italy 11.5.5. Spain 11.5.6. Rest of Europe 11.6. Market Attractiveness Analysis 11.6.1. By Product 11.6.2. By Indication 11.6.3. By End-user 11.6.4. By Country/Sub-region 12. Asia Pacific Nucleic Acid Therapeutics Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast By Product, 2020-2034 12.2.1. Anti-Sense Oligonucleotides (ASO) 12.2.2. RNA Interference (RNAi) 12.2.3. RNA Aptamers 12.3. Market Value Forecast By Indication, 2020-2034 12.3.1. Autoimmune Disorders 12.3.2. Infectious Diseases 12.3.3. Genetic Disorders 12.3.4. Cancer 12.3.5. Others 12.4. Market Value Forecast By End-user, 2020-2034 12.4.1. Hospitals 12.4.2. Physicians’ Offices 12.4.3. Others 12.5. Market Value Forecast By Country/Sub-region, 2020-2034 12.5.1. China 12.5.2. India 12.5.3. Japan 12.5.4. Australia & New Zealand 12.5.5. Rest of Asia Pacific 12.6. Market Attractiveness Analysis 12.6.1. By Product 12.6.2. By Indication 12.6.3. By End-user 12.6.4. By Country/Sub-region 13. Latin America Nucleic Acid Therapeutics Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast By Product, 2020-2034 13.2.1. Anti-Sense Oligonucleotides (ASO) 13.2.2. RNA Interference (RNAi) 13.2.3. RNA Aptamers 13.3. Market Value Forecast By Indication, 2020-2034 13.3.1. Autoimmune Disorders 13.3.2. Infectious Diseases 13.3.3. Genetic Disorders 13.3.4. Cancer 13.3.5. Others 13.4. Market Value Forecast By End-user, 2020-2034 13.4.1. Hospitals 13.4.2. Physicians’ Offices 13.4.3. Others 13.5. Market Value Forecast By Country/Sub-region, 2020-2034 13.5.1. Brazil 13.5.2. Mexico 13.5.3. Rest of Latin America 13.6. Market Attractiveness Analysis 13.6.1. By Product 13.6.2. By Indication 13.6.3. By End-user 13.6.4. By Country/Sub-region 14. Middle East & Africa Nucleic Acid Therapeutics Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast By Product, 2020-2034 14.2.1. Anti-Sense Oligonucleotides (ASO) 14.2.2. RNA Interference (RNAi) 14.2.3. RNA Aptamers 14.3. Market Value Forecast By Indication, 2020-2034 14.3.1. Autoimmune Disorders 14.3.2. Infectious Diseases 14.3.3. Genetic Disorders 14.3.4. Cancer 14.3.5. Others 14.4. Market Value Forecast By End-user, 2020-2034 14.4.1. Hospitals 14.4.2. Physicians’ Offices 14.4.3. Others 14.5. Market Value Forecast By Country/Sub-region, 2020-2034 14.5.1. GCC 14.5.2. South Africa 14.5.3. Rest of Middle East & Africa 14.6. Market Attractiveness Analysis 14.6.1. By Product 14.6.2. By Indication 14.6.3. By End-user 14.6.4. By Country/Sub-region 15. Competition Landscape 15.1. Market Player - Competition Matrix (By Tier and Size of companies) 15.2. Market Share Analysis By Company (2023) 15.3. Company Profiles 15.3.1. Alynylam Pharmaceutials, Inc. 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.1.2. Product Portfolio 15.3.1.3. Financial Overview 15.3.1.4. SWOT Analysis 15.3.1.5. Strategic Overview 15.3.2. BioNTech 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.2.2. Product Portfolio 15.3.2.3. Financial Overview 15.3.2.4. SWOT Analysis 15.3.2.5. Strategic Overview 15.3.3. Ionis Pharmaceuticals, Inc. 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.3.2. Product Portfolio 15.3.3.3. Financial Overview 15.3.3.4. SWOT Analysis 15.3.3.5. Strategic Overview 15.3.4. Moderna 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.4.2. Product Portfolio 15.3.4.3. Financial Overview 15.3.4.4. SWOT Analysis 15.3.4.5. Strategic Overview 15.3.5. Nippon Shinyaku 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.5.2. Product Portfolio 15.3.5.3. Financial Overview 15.3.5.4. SWOT Analysis 15.3.5.5. Strategic Overview 15.3.6. Novartis 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.6.2. Product Portfolio 15.3.6.3. Financial Overview 15.3.6.4. SWOT Analysis 15.3.6.5. Strategic Overview 15.3.7. Pfizer 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.7.2. Product Portfolio 15.3.7.3. Financial Overview 15.3.7.4. SWOT Analysis 15.3.7.5. Strategic Overview 15.3.8. Sarepta Therapeutics 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.8.2. Product Portfolio 15.3.8.3. Financial Overview 15.3.8.4. SWOT Analysis 15.3.8.5. Strategic Overview 15.3.9. Biogen Inc. 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.9.2. Product Portfolio 15.3.9.3. Financial Overview 15.3.9.4. SWOT Analysis 15.3.9.5. Strategic Overview 15.3.10. Genzyme Sanofi 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.10.2. Product Portfolio 15.3.10.3. Financial Overview 15.3.10.4. SWOT Analysis 15.3.10.5. Strategic Overview 15.3.11. Percheron Therapeutics Ltd. 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.11.2. Product Portfolio 15.3.11.3. Financial Overview 15.3.11.4. SWOT Analysis 15.3.11.5. Strategic Overview
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(その他)の最新刊レポート
Transparency Market Research 社の最新刊レポート
本レポートと同じKEY WORD(acid)の最新刊レポート
よくあるご質問Transparency Market Research社はどのような調査会社ですか?トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/09/24 10:26 144.74 円 161.12 円 195.86 円 |